Shortly after claiming FDA approval for its Filspari therapy for rare kidney disease IgA Nephropathy (IgAN), Travere Therapeutics has said it will price the drug at a disc
Swedish biotech Calliditas has raised $90 million in an upsized US IPO and private placement, valuing the rare kidney and liver disease specialist at $467 million as the craze for biotech I